What's the best way for an organization to prepare for the continued digitization and decentralization of trials?
Join a panel of experts across Bristol-Myers Squibb, Cognizant, and Medable as they lead attendees through the key questions and strategies used to set and define digital and decentralized drug development strategies.
Viewers will walk away with a thorough understanding of the benefits and needs of a proper DCT strategy, including:
Alison (Ali) Holland is Head of Decentralized Clinical Trials at Medable and is chartered to design and expand the end-to-end capabilities.
As Chief Scientific Officer, Dr. Pamela Tenaerts oversees Medable’s clinical research department to help identify, develop and implement...